octreotide
information and resources from the National Cancer Institute
octreotide
The synthetic acetate salt of a long-acting cyclic octapeptide with pharmacologic properties mimicking those of the natural hormone somatostatin. Similar to somatostatin, octreotide suppresses the luteinizing hormone response to gonadotropin-releasing hormone, decreases splanchnic blood flow, and inhibits the release of serotonin, gastrin, vasoactive intestinal peptide (VIP), secretin, motilin, pancreatic polypeptide, and thyroid stimulating hormone. octreotide
The synthetic acetate salt of a long-acting cyclic octapeptide with pharmacologic properties mimicking those of the natural hormone somatostatin. Similar to somatostatin, octreotide suppresses the luteinizing hormone response to gonadotropin-releasing hormone, decreases splanchnic blood flow, and inhibits the release of serotonin, gastrin, vasoactive intestinal peptide (VIP), secretin, motilin, pancreatic polypeptide, and thyroid stimulating hormone.
|
|
|
|
news articles
Ambrilia Announces Fiscal 2005 Results and Appointment of Three ... Mar 22, 2006
Genetic Engineering News, ...the $18.1 million equity financing that closed on March 1, 2006 and milestones to be received from existing contracts with licensees for Octreotide, to support ...
Temodar® and Thalomid® Effective for Metastatic Neuroendocrine ... Mar 21, 2006
Cancer Consultants (press release), The introduction of the long-acting somatostatin analogue Sandostatin® (octreotide) has resulted in significant advances in palliation and in controlling ...
Diarrhea: Cancer-related causes and how to cope Mar 2, 2006
MayoClinic.com Examples of anti-secretory agents include aspirin, bismuth subsalicylate (Pepto-Bismol), corticosteroids and octreotide. Fiber. ...
Zollinger-Ellison Syndrome Dec 1, 2005
EndoNurse, Long-term treatment with octreotide, a drug that reduces the amount of growth hormone produced by the body, may also have potential in stabilizing tumors in ...
|
|
